Table I.
Comparison of protein tyrosine phosphatase, non-receptor type 1 methylation levels (%) between cases of T2D and controls.
| Characteristics | Controls | Cases | P-value |
|---|---|---|---|
| All subjects, n=194a | |||
| CpG1 | 12.00±9.03 | 15.98±9.18 | 0.001 |
| CpG2 | 6.41±3.16 | 8.68±4.48 | 0.002 |
| CpG3 | 5.57±1.88 | 6.98±3.11 | 0.001 |
| CpG4 | 15.46±5.76 | 18.87±8.09 | 0.003 |
| CpG5 | 6.23±1.75 | 7.51±3.69 | 0.007 |
| CpG6 | 4.60±0.87 | 5.21±1.24 | 0.001 |
| CpG7 | 4.84±1.39 | 5.15±1.60 | 0.036 |
| CpG8 | 4.37±0.70 | 4.89±0.76 | 0.001 |
| CpG mean | 7.43±2.37 | 9.16±3.02 | 1.34×10−4 |
| Female, n=120b | |||
| CpG1 | 10.77±7.86 | 16.57±9.33 | 0.001 |
| CpG2 | 5.92±2.14 | 8.77±5.02 | 0.001 |
| CpG3 | 5.37±1.88 | 6.78±3.06 | 0.013 |
| CpG4 | 14.80±5.73 | 18.34±8.25 | 0.021 |
| CpG5 | 6.15±1.96 | 7.18±2.03 | 0.044 |
| CpG6 | 4.51±0.92 | 5.23±1.29 | 0.006 |
| CpG7 | 4.59±0.90 | 5.07±0.94 | 0.023 |
| CpG8 | 4.26±0.76 | 4.84±0.71 | 1.00×10−3 |
| CpG mean | 7.05±2.15 | 9.10±3.12 | 4.82×10−4 |
| Male, n=74c | |||
| CpG1 | 14.00±10.46 | 15.02±8.96 | 0.918 |
| CpG2 | 7.20±4.25 | 8.53±3.48 | 0.570 |
| CpG3 | 5.90±1.86 | 7.29±3.21 | 0.067 |
| CpG4 | 16.51±5.74 | 19.75±7.85 | 0.072 |
| CpG5 | 6.35±1.36 | 8.06±5.40 | 0.101 |
| CpG6 | 4.74±0.78 | 5.17±1.16 | 0.128 |
| CpG7 | 5.24±1.88 | 5.28±2.32 | 0.536 |
| CpG8 | 4.54±0.58 | 4.96±0.85 | 0.436 |
| CpG mean | 8.06±2.61 | 9.26±2.89 | 0.192 |
a
DNA methylation in the T2D controls and cases was adjusted for smoking, drinking, TG and CRE in all subjects.
b
DNA methylation in T2D controls and cases was adjusted for drinking, triglyceride, low-density lipoprotein and uric acid in females.
c
DNA methylation in T2D controls and cases was adjusted for drinking, smoking and creatinine in males. Results are expressed as the mean ± standard deviation. CpGs, cytosine-guanine dinucleotide sites; T2D, type 2 diabetes.